AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
A Reckoning for the Magnificent Seven Tests the Market
Alphabet, Amazon, Apple, Meta, Microsoft, Nvidia and Tesla are collectively off to their worst start since the 2022 slide, worrying investors. Continue Reading View Comments
- April 26, 2025 06:00 PM PDT
- EODHD
Amateur Athletes Are Turning to Ozempic to Raise Their Game
Runners, cyclists and other fitness enthusiasts say weight-loss drugs give them a performance edge, despite potential risks. Continue Reading View Comments
- April 26, 2025 06:00 PM PDT
- EODHD
Meta’s ‘Digital Companions’ Will Talk Sex With Users—Even Children
Chatbots on Instagram, Facebook and WhatsApp are empowered to engage in ‘romantic role-play’ that can turn explicit. Some people inside the company are concerned. Continue Reading View Comments
- April 26, 2025 05:30 PM PDT
- EODHD
Renewables Emerge as Key to Meet AI-Driven Energy Demand
The operator of the largest gas-fired electricity generation fleet in America believes that renewables will be vital to meet the rise in power demand driven by AI and the reshoring of manufacturing. N...
- April 26, 2025 04:00 PM PDT
- EODHD
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
CG Oncology Inc. - Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C – - 58.3% of patients showed durable complete responses by K-M at 24 month...
- April 26, 2025 01:10 PM PDT
- EODHD
Tech Executives Are Starting to Talk Tariffs. What It May Mean for Apple, Amazon Earnings
Amazon, Apple, Meta and Microsoft will need to address tariffs on earnings calls next week. Tech executives are sounding alarms. Continue Reading View Comments
- April 26, 2025 11:14 AM PDT
- EODHD
Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
Pivotal Phase 3 CREST trial results show a 32% reduction in the risk of disease-related events, including high-grade disease recurrence or progression, with sasanlimab in combination with standard of...
- April 26, 2025 10:30 AM PDT
- EODHD
Akeso survival data for ivonescimab misses expectations, STAT says
While Akeso (AKESF) and Summit Therapeutics’ (SMMT) ivonescimab, a rival to Merck’s (MRK) Keytruda, won approval in China this week, the data on patient survival did not meet analyst expectations, Jon...
- April 26, 2025 09:50 AM PDT
- EODHD
Biohaven share price undervaluing pipeline potential, says RBC Capital
RBC Capital points out that notes released by the European Medicines Agency’s CHMP indicated that Biohaven (BHVN) had withdrawn the application for troriluzole in spinocerebellar ataxia. Investor sent...
- April 26, 2025 09:10 AM PDT
- EODHD
Bob Bakish was ousted by Paramount after clashing with Shari Redstone and he still got rewarded with a $69.3 million golden parachute
Bob Bakish, who was ousted as CEO of Paramount in last April, received $69.3 million as part of his severance compensation. The package was revealed in a Paramount filing disclosed by the SEC on Frida...
- April 26, 2025 08:23 AM PDT
- EODHD